

# Biomed Industries Unveils Novel Quadruple Receptor Agonist for Weight Loss at International Obesity Conference

*Biomed Industries Unveils Novel Quadruple Receptor Agonist for Weight Loss with Minimal Adverse Effects at the International Obesity Conference in Las Vegas*

SAN JOSE, CA, UNITED STATES,  
September 23, 2024 /

[EINPresswire.com/](https://www.einpresswire.com/) -- [Biomed Industries, Inc.](https://www.biomedindustries.com/), a leading

biopharmaceutical company,

announces a major breakthrough in obesity treatment with the introduction of NA-931, a novel quadruple receptor agonist targeting IGF-1, GLP-1 GIP, and Glucagon. This innovative therapy represents significant advancement in weight loss, offering key advantages over current

medications that primarily focus on GLP-1 or dual receptor GLP-1 and GIP combinations.

“

NA-931, a quadruple receptor agonist provides a superior method for treating obesity, while preserving muscle mass and minimizing the serious side effects often associated with current treatments.”

*Dr. Lloyd L. Tran, CEO of  
Biomed*

Dr. Lloyd L. Tran, CEO of Biomed Industries, will deliver a keynote presentation titled "NA-931: A Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight Without Muscle Loss" at the International Conference on Obesity and Weight Management, which will take place in Las Vegas on October 16-17, 2024.

Obesity, a chronic disease affecting approximately 650 million people worldwide, is characterized by excess adiposity that impairs health and results from a complex


interplay of genetic, behavioral, and social factors. Current treatments often target only a subset of obesity's underlying causes, leaving room for improved, multi-faceted approaches.

NA-931, developed for oral administration, is currently in Phase 2 clinical trials. Preclinical studies have demonstrated that NA-931 can lead to substantial body weight reduction of up to



26% ( $p < 0.0001$ ) along with significant reductions in plasma glucose (23%) and plasma triglycerides (34%,  $p < 0.003$  for each). Unlike many existing therapies, NA-931 not only promotes weight loss but also preserves muscle mass, while showing a lower incidence of adverse effects typically associated with current obesity treatments.

The quadruple action mechanism of NA-931 harnesses the combined effects of Insulin-like Growth Factor 1 (IGF-1), which plays a pivotal role in fuel metabolism and body composition regulation. The additional roles of GIP, GLP-1, and Glucagon make NA-931 effective in promoting weight loss, particularly in non-diabetic patients with obesity, when used alongside diet and exercise. Furthermore, IGF-1 helps modulate glucagon secretion by inhibiting low glucose-induced glucagon expression, adding another layer of metabolic control.



NA-931 to treat diabetes obesity

### NA-931 for weight loss

Clinical Programs	Phase 1	Phase 2	Phase 3	Marketing
NA-704 Amyotrophic Lateral Sclerosis (ALS) (Phase 2A)	→			
NA-831 Mild and Moderate Alzheimer's disease (Phase 2B/3)	→			
NA-901 Major Depressive Disorder (MDD) (Phase 2B/3)	→			
NA-911 Stroke (Phase 2A)	→			
NA-921 Rett Syndrome and Fragile X Syndrome (Phase 2B/3)	→			
NA-931 Diabetes Obesity & Weight Loss (Phase 2B/3)	→			
NA-941 Metabolic dysfunction-associated steatohepatitis (MASH) (Phase 2A)	→			
MICROS Intravenous drug delivery system (FDA Approved in the USA)	→			

Biomed pipeline

“We've achieved a significant breakthrough by harnessing the synergistic actions of four key growth hormone receptors and their agonists. This has resulted in remarkable outcomes for obesity treatment with NA-931,” said Dr. Lloyd L. Tran, Chairman and CEO of Biomed Industries. “We identified the fourth receptor agonist that regulates the homeostasis of GLP-1, GIP, and Glucagon receptors. This quadruple-pathway approach not only provides a superior method for treating obesity but also preserves muscle mass, all while minimizing the serious side effects often associated with current treatments.”

About Biomed Industries, Inc.:

Biomed Industries, Inc. is a pioneering biopharmaceutical company dedicated to developing and commercializing novel therapeutics to address unmet medical needs. The company's innovative research platform has led to the development of treatments for conditions including Alzheimer's disease, ALS, Traumatic Brain Injury, Major Depressive Disorder (MDD), Diabetes, Obesity, MASH, Stroke, and rare diseases such as Rett Syndrome.

For more information, visit our official website :

[https:// www.biomedind.com](https://www.biomedind.com)

CONTACT

Michael Willis  
Biomed Industries, Inc.  
San Jose, CA 95131 USA  
Tel: 800-824-5135  
Email: [media@biomedind.com](mailto:media@biomedind.com)  
Website: [[www.biomedind.com](http://www.biomedind.com)](<https://www.biomedind.com>)

Dr. Lloyd L. Tran  
Biomed Industries, Inc.  
+1 800-824-5135  
[email us here](#)

Visit us on social media:

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/745492515>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.